Zomedica Pharmaceuticals Company Leadership
| ZOM Stock | USD 0.12 0 2.50% |
Zomedica Pharmaceuticals employs about 144 people. The company is managed by 32 executives with a total tenure of roughly 57 years, averaging almost 1.0 years of service per executive, having 4.5 employees per reported executive. Analysis of Zomedica Pharmaceuticals' management performance can provide insight into the firm performance.
| Shameze Rampertab CEO Interim Chief Executive Officer, Chief Financial Officer, Executive Director |
| Jeffrey Rowe Chairman Chairman of the Board |
Zomedica |
Zomedica Pharmaceuticals Management Team Effectiveness
The company has Return on Asset of (0.0929) % which means that on every $100 spent on assets, it lost $0.0929. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2392) %, meaning that it generated no profit with money invested by stockholders. Zomedica Pharmaceuticals' management efficiency ratios could be used to measure how well Zomedica Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 13th of December 2024, Return On Tangible Assets is likely to drop to -0.27. In addition to that, Return On Capital Employed is likely to drop to -0.14. At this time, Zomedica Pharmaceuticals' Intangible Assets are very stable compared to the past year. As of the 13th of December 2024, Intangibles To Total Assets is likely to grow to 0.48, while Net Current Asset Value is likely to drop about 113.7 K.As of the 13th of December 2024, Common Stock Shares Outstanding is likely to grow to about 1 B, while Net Loss is likely to drop (16.1 M).
Zomedica Pharmaceuticals Workforce Comparison
Zomedica Pharmaceuticals Corp is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 12,520. Zomedica Pharmaceuticals claims roughly 144 in number of employees contributing just under 2% to equities under Health Care industry.
Zomedica Pharmaceuticals Profit Margins
The company has Net Profit Margin of (2.15) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (1.47) %, which entails that for every $100 of revenue, it lost $1.47.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.79 | 0.6876 |
|
|
Zomedica Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Zomedica Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Zomedica Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Zomedica Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Zomedica Pharmaceuticals Notable Stakeholders
A Zomedica Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Zomedica Pharmaceuticals often face trade-offs trying to please all of them. Zomedica Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Zomedica Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Robert Cohen | Interim Chief Executive Officer, Director | Profile | |
| Shameze Rampertab | Interim Chief Executive Officer, Chief Financial Officer, Executive Director | Profile | |
| Larry II | CEO President | Profile | |
| Jeffrey Rowe | Chairman of the Board | Profile | |
| Stephanie Morley | President, Chief Operating Officer | Profile | |
| Ann Cotter | Interim Chief Financial Officer, Corporate Secretary | Profile | |
| Thomas Robitaille | Independent Director | Profile | |
| Johnny Powers | Independent Director | Profile | |
| Jane Eagleson | Independent Director | Profile | |
| Angy Guerrant | Director of Portfolio Management | Profile | |
| William MacArthur | Executive Member and Chief Medical Officer, Director of Research and Development | Profile | |
| Robert DiMarzo | Consultant | Profile | |
| Rodney Williams | Independent Member | Profile | |
| Evan Peter | VP Innovation | Profile | |
| MBA BSBA | Chief Officer | Profile | |
| Adrian Lock | GM VP | Profile | |
| Ann CPA | Chief Officer | Profile | |
| Mike Zuehlke | Vice Controller | Profile | |
| Nicole Westfall | VP Marketing | Profile | |
| Christopher MacLeod | Independent Director | Profile | |
| Evan MBA | Vice Innovation | Profile | |
| DVM DVM | Consultant | Profile | |
| Anthony Blair | Chief Officer | Profile | |
| Kristin Domanski | Vice Resources | Profile | |
| Angie Moricz | Executive Administrative Assistant | Profile | |
| Nicole MBA | Senior Marketing | Profile | |
| Karen JD | General Secretary | Profile | |
| Greg Blair | Senior Planning | Profile | |
| Russell Klass | Senior Sales | Profile | |
| Christopher Wolfenberg | Director | Profile | |
| Andrea Eberle | Senior Marketing Manager | Profile | |
| Bruk Herbst | Chief Commercial Officer | Profile |
About Zomedica Pharmaceuticals Management Performance
The success or failure of an entity such as Zomedica Pharmaceuticals often depends on how effective the management is. Zomedica Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Zomedica management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Zomedica management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.25) | (0.27) | |
| Return On Capital Employed | (0.13) | (0.14) | |
| Return On Assets | (0.14) | (0.14) | |
| Return On Equity | (0.14) | (0.15) |
Zomedica Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Zomedica Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Zomedica Pharmaceuticals within its industry.Zomedica Pharmaceuticals Manpower Efficiency
Return on Zomedica Pharmaceuticals Manpower
| Revenue Per Employee | 174.9K | |
| Revenue Per Executive | 787.1K | |
| Net Loss Per Employee | 239.8K | |
| Net Loss Per Executive | 1.1M | |
| Working Capital Per Employee | 630.9K | |
| Working Capital Per Executive | 2.8M |
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.06) | Revenue Per Share 0.027 | Quarterly Revenue Growth 0.018 | Return On Assets (0.09) | Return On Equity (0.24) |
The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zomedica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.